Cypherpunk Technologies Inc. (CYPH)
NASDAQ:CYPH
CYPH Stock Chart & Stats
$1.00
$0.19(23.79%)
―
--
Day’s Range― - ―
52-Week Range$0.23 - $3.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.93M
Market Cap
$89.89M
Enterprise Value$42.60M
Total Cash (Recent Filing)$14.04M
Total Debt (Recent Filing)$38.00K
Price to Earnings (P/E)15.9
Beta0.71
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares Outstanding89,979,620
10 Day Avg. Volume1,410,293
30 Day Avg. Volume1,933,158
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue203.82
Enterprise Value/Gross Profit-2.12
Enterprise Value/Ebitda-1.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Equity BaseThe company’s near-zero debt and large equity position provide durable financial flexibility. This capital buffer reduces bankruptcy and refinancing risk, supports continued operations during cash burn, and enables strategic moves or asset purchases without immediate external financing over the next several months.
Material Asset And Equity Growth; ROE ImprovementSignificant growth in assets and equity alongside a ~10% ROE indicates improving capital efficiency and a stronger capital base. This structural improvement supports long-term resilience by increasing loss-absorption capacity and improving options to invest in growth or shore up operations without immediate dilution.
GAAP Net Income Swung Positive In 2025A positive net income in 2025, after multiple years of losses, demonstrates an ability to deliver bottom-line profitability at least on a GAAP basis. Sustaining this improvement can materially reduce financing dependence and supports a narrative of operational or non-operational gains that improve long-term solvency.
Bears Say
Effectively Zero RevenueThe absence of meaningful revenue undermines the core business model and operating leverage. Without a recurring revenue base, profitability is fragile and dependent on one-off gains or asset sales, making long-term sustainability and organic growth unlikely over the next several months.
Persistent Operating Cash BurnConsistent negative operating and free cash flow (-43.9M for 2025) shows the business cannot self-fund operations. Reliance on balance-sheet resources to cover cash burn creates financing risk: if reserves decline or markets tighten, the company may need dilutive or costly funding within months.
Nasdaq Minimum Bid Deficiency / Listing RiskA formal Nasdaq deficiency introduces structural listing risk and potential liquidity loss if not cured. The need to regain a $1.00 bid or pursue corporate actions (reverse split) creates execution risk and could constrain strategic flexibility, investor base, and access to capital over the coming months.
Cypherpunk Technologies News
CYPH FAQ
What was Cypherpunk Technologies Inc.’s price range in the past 12 months?
Cypherpunk Technologies Inc. lowest stock price was $0.23 and its highest was $3.70 in the past 12 months.
What is Cypherpunk Technologies Inc.’s market cap?
Cypherpunk Technologies Inc.’s market cap is $89.89M.
When is Cypherpunk Technologies Inc.’s upcoming earnings report date?
Cypherpunk Technologies Inc.’s upcoming earnings report date is May 18, 2026 which is in 38 days.
How were Cypherpunk Technologies Inc.’s earnings last quarter?
Cypherpunk Technologies Inc. released its earnings results on Mar 16, 2026. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.986.
Is Cypherpunk Technologies Inc. overvalued?
According to Wall Street analysts Cypherpunk Technologies Inc.’s price is currently Undervalued.
Does Cypherpunk Technologies Inc. pay dividends?
Cypherpunk Technologies Inc. does not currently pay dividends.
What is Cypherpunk Technologies Inc.’s EPS estimate?
Cypherpunk Technologies Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cypherpunk Technologies Inc. have?
Cypherpunk Technologies Inc. has 89,979,620 shares outstanding.
What happened to Cypherpunk Technologies Inc.’s price movement after its last earnings report?
Cypherpunk Technologies Inc. reported an EPS of $0.92 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 12.642%.
Which hedge fund is a major shareholder of Cypherpunk Technologies Inc.?
Currently, no hedge funds are holding shares in CYPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cypherpunk Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $42.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
201.11%
12-Months-Change
Fundamentals
Return on Equity
-16.90%
Trailing 12-Months
Asset Growth
249.73%
Trailing 12-Months
Company Description
Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Ownership Overview
2.76% Insiders
2.38%
Mutual Funds
0.10% Other Institutional Investors
92.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---